Seeking Alpha

Pharmasset (VRUS) drops 3.6% after announcing it will "discontinue all treatment" in ongoing...

Pharmasset (VRUS) drops 3.6% after announcing it will "discontinue all treatment" in ongoing Phase 2b trials that involves use of its PSI-938 hepatitis drug. The company says it "detected laboratory abnormalities associated with liver function" in patients using PSI-938.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs